SCHEMBL777282

SCHEMBL777282

CCc1ccccc1OS(=O)(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 1/20 0.48
L3MBTL1 Q9Y468 5/20 0.47
MAPT P10636 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
SLC22A6 Q4U2R8 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.41
HPGD P15428 1/20 0.41
ATM Q13315 1/20 0.41
FABP1 P07148 1/20 0.41
GABRA1 P14867 1/20 0.40
GABRB2 P47870 1/20 0.40
TSHR P16473 1/20 0.39
HSD17B10 Q99714 1/20 0.39
KDM4E B2RXH2 2/20 0.38
CA5A P35218 2/20 0.38
NISCH Q9Y2I1 1/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA9 Q16790 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL9821309 0.98 DHODH (0.47) DHODHL3MBTL1MAPTNPSR1SLC22A6
SCHEMBL7724404 0.87 PPARD (0.43) DHODHSLC22A6FABP1CA5ANISCH
SCHEMBL5433099 0.84 THRA (0.48)
SCHEMBL777281 0.83 L3MBTL1 (0.50) DHODHL3MBTL1MAPTNPSR1SMN1; SMN2
Ethane SCHEMBL7364126 0.83 SLC22A6 (0.40) DHODHSLC22A6SMN1; SMN2FABP1KDM4E
SCHEMBL1101443 0.83 THRA (0.54)
SCHEMBL27465342 0.82 SLC22A6 (0.42) DHODHSLC22A6SMN1; SMN2FABP1KDM4E
SCHEMBL4132734 0.82 KAT6A (0.40) DHODHL3MBTL1MAPTNPSR1SLC22A6
SCHEMBL327172 0.81 THRA (0.56)
Ammonia Solution, Strong SCHEMBL371312 0.81 THRA (0.52)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240019417-A1 Methods and Systems for Determining Autism Spectrum Disorder Risk LABORATORY CORPORATION OF AMERICA HOLDINGS (US) 2024-01-18 US claimed
US-20220050090-A1 MASS SPECTROMETRY ASSAY METHOD FOR DETECTION AND QUANTITATION OF MICROBIOTA RELATED METABOLITES METABOLON, INC. 2022-02-17 US claimed
EP-3850359-A1 MASS SPECTROMETRY ASSAY METHOD FOR DETECTION AND QUANTITATION OF MICROBIOTA-RELATED METABOLITES Metabolon Inc. (US) 2021-07-21 EP claimed
WO-2020055631-A1 MASS SPECTROMETRY ASSAY METHOD FOR DETECTION AND QUANTITATION OF MICROBIOTA-RELATED METABOLITES METABOLON, INC. (US) 2020-03-19 WO claimed
US-20180235987-A1 GLYCAN COMPOSITIONS AND USES THEREOF HERCULES CAPITAL, INC. 2018-08-23 US claimed
EP-3071235-A1 GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF Kaleido Biosciences, Inc. (US) 2016-09-28 EP claimed
WO-2016122889-A1 GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF KALEIDO BIOSCIENCES, INC. (US) 2016-08-04 WO claimed
US-20260034086-A1 Pet Food Compositions Comprising Caprylic Acid And Docosahexaenoic Acid And/Or Eicosapetaenoic Acid For Use In Treating Struvite Urolithiasis HILL'S PET NUTRITION, INC. (US) 2026-02-05 US disclosed
US-12458617-B2 Pet food compositions comprising caprylic acid and docosahexaenoic acid and/or eicosapetaenoic acid for use in treating struvite urolithiasis HILL'S PET NUTRITION, INC. (US) 2025-11-04 US disclosed
US-12377113-B2 Glycan therapeutic compositions and related methods thereof DSM NUTRITIONAL PRODUCTS, LLC (US) 2025-08-05 US disclosed
US-12100809-B2 Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery MITSUBISHI CHEMICAL CORPORATION (JP) 2024-09-24 US disclosed
EP-3967217-B1 BLOOD BASED BIOMARKERS FOR DIAGNOSING ATHEROSCLEROTIC CORONARY ARTERY DISEASE GLOBAL GENOMICS GROUP LLC (US) 2024-08-14 EP disclosed
US-20240108642-A1 GLYCAN THERAPEUTIC COMPOSITIONS AND RELATED METHODS THEREOF DSM NUTRITIONAL PRODUCTS, LLC 2024-04-04 US disclosed
CN-1278953-A Nonaqueous electrolyte battery MITSUBISHI CHEM CORP (JP) 2001-01-03 CN disclosed
EP-0410976-A4 HEAT STABLE QUATERNIZED LACTAMS HAVING OXYLATED SULFUR ANIONS 1991-10-16 EP disclosed
EP-0410976-A1 HEAT STABLE QUATERNIZED LACTAMS HAVING OXYLATED SULFUR ANIONS GAF CHEMICALS CORPORATION (US) 1991-02-06 EP disclosed
US-4957731-A CONDITIONERS, QUATERNIZED LACTAMS GAF CHEMICALS CORPORATION (US) 1990-09-18 US disclosed
US-4885158-A Heat stable quaternized lactams having oxylated sulfur anions GAF CORPORATION (US) 1989-12-05 US disclosed
WO-1989010115-A1 HAIR PROCESSING ADDITIVES GAF CHEMICALS CORPORATION (US) 1989-11-02 WO disclosed
WO-1989010358-A1 HEAT STABLE QUATERNIZED LACTAMS HAVING OXYLATED SULFUR ANIONS GAF CHEMICALS CORPORATION (US) 1989-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034086-A1 Pet Food Compositions Comprising Caprylic Acid And Docosahexaenoic Acid And/Or Eicosapetaenoic Acid For Use In Treating Struvite Urolithiasis FPR2, FPR1, FPR3 DHODH 3571/4885L3MBTL1 3965/4885MAPT 2558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.